Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy

被引:0
|
作者
Hardev Pandha
Jonathan Eaton
Rebecca Greenhalgh
Diane Soars
Angus Dalgleish
机构
[1] St George's Hospital Medical School,Department of Oncology
[2] Cranmer Terrace,undefined
来源
Cancer Gene Therapy | 2005年 / 12卷
关键词
HSV-tk; cancer vaccine;
D O I
暂无
中图分类号
学科分类号
摘要
Whole cell cancer vaccines are currently under clinical evaluation. Their immunogenicity may depend on the mode of death of the vaccine cells prior to uptake by professional antigen-presenting cells and crosspriming of T cells. Destruction of tumor in vivo by genetic prodrug activation therapy leads to a marked local and systemic immune response, local T-cell infiltration and the establishment of T-cell memory. We postulated that this immunostimulation may be due to induction of danger signals and the inherent immunogenicity of products of HSVtk/ganciclovir kill. Using established models of murine prostate cancer, we have evaluated the efficacy of anti-tumor vaccines comprising irradiated allogeneic or autologous whole cells expressing HSVtK, which are first killed in vitro by prodrug activation using ganciclovir. HSVtk/ganciclovir-induced cell kill was through the induction of apoptosis. The vaccine was found to be effective in both models and superior to traditional irradiated whole tumor cells even after single doses. Protection against tumor challenge was associated with marked proliferative and Th1 cytokine responses. This approach would be applicable clinically in terms of ease of vaccine production, safety, storage and avoidance of potential toxicities of in vivo gene transfer.
引用
收藏
页码:572 / 578
页数:6
相关论文
共 50 条
  • [21] Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells
    Mariana Berenstein
    Soraya Adris
    Fernanda Ledda
    Claudia Wolfmann
    Jorge Medina
    Alicia Bravo
    Jose Mordoh
    Yuti Chernajovsky
    Osvaldo L Podhajcer
    Cancer Gene Therapy, 1999, 6 : 358 - 366
  • [22] A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase ganciclovir system for the treatment of refractory or recurrent ovarian cancer
    Link, CJ
    Moorman, D
    Seregina, T
    Levy, JP
    Schabold, KJ
    HUMAN GENE THERAPY, 1996, 7 (09) : 1161 - 1179
  • [23] Drug resistance to ganciclovir observed in suicide gene therapy is due to the loss of integrated herpes simplex virus-thymidine kinase gene
    Kimura, M
    Tagawa, M
    Takenaga, K
    Nakagawara, A
    Horitsu, K
    Yamaguchi, T
    Saisho, H
    Sakiyama, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 10 (04) : 775 - 778
  • [24] Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects
    Nicholas, TW
    Read, SB
    Burrows, FJ
    Kruse, CA
    HISTOLOGY AND HISTOPATHOLOGY, 2003, 18 (02) : 495 - 507
  • [25] Tumor killing using the herpes simplex virus thymidine kinase (HSV-TK) suicide gene
    Freeman, SM
    Ramesh, R
    Munshi, A
    CANCER GENE THERAPY, 1998, 5 (06) : S16 - S17
  • [26] Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir
    Deng, WP
    Yang, WK
    Lai, WF
    Liu, RS
    Hwang, JJ
    Yang, DM
    Fu, YK
    Wang, HE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (01) : 99 - 109
  • [27] GENE-THERAPY FOR THE TREATMENT OF MALIGNANT BRAIN-TUMORS WITH IN-VIVO TUMOR TRANSDUCTION WITH THE HERPES-SIMPLEX THYMIDINE KINASE GENE GANCICLOVIR SYSTEM
    CULVER, KW
    VANGILDER, J
    LINK, CJ
    CARLSTROM, T
    BUROKER, T
    YUH, W
    KOCH, K
    SCHABOLD, K
    DOORNBAS, S
    WETJEN, B
    BLAESE, RM
    HUMAN GENE THERAPY, 1994, 5 (03) : 343 - 379
  • [28] GENE-THERAPY FOR THE TREATMENT OF RECURRENT PEDIATRIC MALIGNANT ASTROCYTOMAS WITH IN-VIVO TUMOR TRANSDUCTION WITH THE HERPES-SIMPLEX THYMIDINE KINASE GENE GANCICLOVIR SYSTEM
    RAFFEL, C
    CULVER, K
    KOHN, D
    NELSON, M
    SIEGEL, S
    GILLIS, F
    LINK, CJ
    VILLABLANCA, JG
    ANDERSON, WF
    HUMAN GENE THERAPY, 1994, 5 (07) : 863 - 890
  • [29] Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir
    Win-Ping Deng
    Wen K. Yang
    Wen-Fu Lai
    Ren-Shyan Liu
    Jeng-Jong Hwang
    Den-Mei Yang
    Ying-Kai Fu
    Hsin-Ell Wang
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 99 - 109
  • [30] Effect of gene therapy with the herpes simplex virus thymidine kinase gene on hepatic metastasis in murine colon cancer
    Hayashi, S
    Emi, N
    Yokoyama, I
    Uchida, K
    Takagi, H
    SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1997, 27 (01): : 40 - 43